SI-BONE, Inc. initiated a voluntary Class II recall of 98 iFuse TORQ implants from specific lots due to tube packaging failures that compromised sterility. Two implants had already been implanted in patients; no infections have been reported. The company expects approximately 3,900 total implants to require repackaging and re-sterilization. SI-BONE anticipates recording an aggregate gross charge of up to $150,000 in the third and fourth quarters for recall and remediation costs, with potential recovery sought from the tube manufacturer. The company does not believe this will materially impact revenue or its ability to provide implants. Separately, SI-BONE entered into a Fourth Amendment to Lease extending its Santa Clara headquarters lease by one month at $43,696 per month. SI-BONE, Inc. operates in the medical device industry, specializing in minimally invasive spine implant systems.

SI-BONE, Inc. reported financial results for the quarter ended June 30, 2026, announcing worldwide revenue of $56.0 million, a 15.2% increase year-over-year. The company achieved positive adjusted EBITDA of $2.8 million and a net loss of $4.1 million, an improvement of 33.6%. SI-BONE raised its full-year 2026 revenue guidance to $231–$233 million, implying ~15-16% growth, while maintaining gross margin guidance at ~79%. The U.S. physician base grew 19% to 1,715 active physicians, and the company submitted a 510(k) application for a new breakthrough device in June. SI-BONE operates in the medical technology industry, developing procedural solutions for compromised bone.

SI-BONE, Inc. entered into a Third Amendment to Lease for its corporate headquarters, extending the lease for one month starting August 1, 2026, with a monthly base rent of $43,696. Additionally, the company reported the results of its Annual Meeting of Stockholders, where directors were elected, the independent auditor was ratified, and executive compensation was approved on an advisory basis.